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Evaluation of Initial and Steady-State Gatifloxacin Pharmacokinetics
and Dose in Pulmonary Tuberculosis Patients by Using Monte Carlo
Simulations
Wynand Smythe,a Corinne S. Merle,b Roxana Rustomjee,c Martin Gninafon,d Mame Bocar Lo,e Oumou Bah-Sow,f Piero L. Olliaro,g
Christian Lienhardt,h John Horton,i Peter Smith,a Helen McIlleron,a,j Ulrika S. H. Simonssonk
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africaa; Faculty of Epidemiology & Population Health, Tropical
Epidemiological Group, London School of Hygiene & Tropical Medicine, London, United Kingdomb; Unit for Clinical & Biomedical TB Research, Medical Research Council
(MRC), Durban, South Africac; Programme National de Lutte contre la Tuberculose, Cotonou, Benind; Programme National de Lutte contre la Tuberculose, Dakar-Fann,
Senegale; Service Pneumo-phtisiologie, CHU Ignace Deen, Conakry, Guineaf; UNICEF/UNDP/World Bank/WHO Special Programme on Research & Training in Tropical
Diseases (TDR), World Health Organization, Switzerlandg; Institut de recherche pour le Développement (IRD), Paris, Franceh; Tropical Projects, Hitchin, United Kingdomi;
Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africaj; Department of Pharmaceutical Biosciences, Uppsala University,
Uppsala, Swedenk
A 4-month regimen of gatifloxacin with rifampin, isoniazid, and pyrazinamide is being evaluated for the treatment of tuberculo-
sis in a phase 3 randomized controlled trial (OFLOTUB). A prior single-dose study found that gatifloxacin exposure increased by
14% in the combination. The aims of the study are to evaluate the initial and steady-state pharmacokinetics of gatifloxacin when
daily doses are given to patients with newly diagnosed drug-sensitive pulmonary tuberculosis as part of a combination regimen
and to evaluate the gatifloxacin dose with respect to the probability of attaining a pharmacokinetic/pharmacodynamic target.
We describe the population pharmacokinetics of gatifloxacin from the first dose to a median of 28 days in 169 adults enrolled in
the OFLOTUB trial in Benin, Guinea, Senegal, and South Africa. The probability of achieving a ratio of>125 for the area under
the concentration time curve to infinity (AUC0–) for the free fraction of gatifloxacin over the MIC (fAUC/MIC) was investi-
gated usingMonte Carlo simulations. The median AUC0– of 41.2g · h/ml decreased on average by 14.3% (90% confidence
interval [CI],90.5% to61.5%) following multiple 400-mg daily doses. At steady state, 90% of patients achieved an fAUC/MIC
of>125 only when theMIC was<0.125g/ml. We conclude that systemic exposure to gatifloxacin declines with repeated daily
400-mg doses when used together with rifampin, isoniazid, and pyrazinamide, thus compensating for any initial increase in gati-
floxacin levels due to a drug interaction. (The OFLOTUB study has been registered at ClinicalTrials.gov under registration no.
NCT00216385.)
Fluoroquinolones represent a promising class of drug for thetreatment of tuberculosis. Gatifloxacin distributes widely
throughout the body (1), achieving MICs for Mycobacterium tu-
berculosis observed in vitro of 0.031 to 0.5 g/ml (2, 3, 4), and
demonstrates strong bactericidal activity in the mouse model (2,
5). Furthermore, gatifloxacin displays excellent early bactericidal
activity (EBA), only slightly lower than that of isoniazid (6); re-
placing ethambutol with gatifloxacin in the standard first-line reg-
imen resulted in accelerated killing of M. tuberculosis in the spu-
tum of patients with pulmonary tuberculosis (7). A single-dose
crossover study in healthy volunteers showed a reduction in the
elimination rate of gatifloxacin resulting in a 14% increase in the
area under the concentration time curve to infinity (AUC0–)
when it was given together with rifampin, isoniazid, and pyrazin-
amide (8). Reports of dysglycemia related to the use of gatifloxacin
in elderly patients with renal insufficiency (9, 10, 11, 12) have
raised concerns that pharmacokinetic interactions may lead to an
increased risk of toxicity related to higher gatifloxacin exposure.
On the other hand, in vitro and in vivo studies suggest a target ratio
of125 for the free drug area under the concentration versus time
curve to MIC (fAUC/MIC) for maximal bactericidal effect and
prevention of resistance to fluoroquinolones (13, 14).
We aimed to evaluate the population pharmacokinetics of gati-
floxacin after an initial dose and at steady state (28 days) when
given in combination with rifampin, isoniazid, and pyrazinamide
in African adult patients with newly diagnosed pulmonary tuber-
culosis. In addition, the probability of target (fAUC/MIC 125)
attainment (PTA) and the cumulative fraction of response (CFR)
(15) across the MIC distribution of M. tuberculosis for 400, 600,
and 800 mg once daily of gatifloxacin at steady state in combina-
tion with rifampin, isoniazid, and pyrazinamide were investigated
with Monte Carlo simulations using the final model.
MATERIALS AND METHODS
Patients.Newly diagnosed pulmonary tuberculosis patients participating
in the multicenter phase 3 randomized controlled trial (OFLOTUB trial
[ClinicalTrials.gov registration no. NCT00216385]) (16) at clinics in
South Africa, Senegal, Guinea, and Benin were enrolled in the pharmaco-
kinetic study, and those randomized to the 4-month regimen of gatifloxa-
cin, rifampin, isoniazid, and pyrazinamide (n 169)were included in this
analysis. Written informed consent was obtained prior to enrollment.
Adult males (n 116) and nonpregnant females (n 53), aged 18 to 58
years and weighing 35 to 80 kg were included in this analysis. HIV-in-
fected patients (n  54) were antiretroviral naive. During the first 2
Received 14 March 2013 Returned for modification 4 May 2013
Accepted 10 June 2013
Published ahead of print 17 June 2013
Address correspondence to Helen McIlleron, helen.mcilleron@uct.ac.za.
Copyright © 2013, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.00479-13
4164 aac.asm.org Antimicrobial Agents and Chemotherapy p. 4164–4171 September 2013 Volume 57 Number 9
months of treatment, all patients received 400 mg gatifloxacin (Lupin
Pharmaceuticals Pvt Ltd., Mumbai, India) daily irrespective of weight
together with a fixed combination of rifampin, isoniazid, and pyrazin-
amide (Lupin Pharmaceuticals Pvt Ltd., Mumbai, India) as follows: ri-
fampin, 150 mg; isoniazid, 75 mg; and pyrazinamide, 400 mg; patients
weighing 50 kg received 3 tablets, and patients weighing 50 kg re-
ceived 4 tablets. All doses were given orally for 6 days of theweek, and dose
taking was supervised using directly observed therapy (DOT) performed
either by health center staff or designated representatives for the duration
of the study.
Blood sampling. Three venous blood samples per patient were taken
after the first dose (initial dose) and repeated after approximately 28 days
(steady state) for the determination of gatifloxacin pharmacokinetics.
Samples were drawn 1 to 2 and 2.5 to 3.5 h postdose from each patient on
both occasions. Patients were block randomized to a time for the third
sample. After the first dose, the third sample was taken 4 to 6 h postdose
from one half of the patients, and the remaining patients had a sample
taken 8 to 10 h postdose. At steady state, the third sample was taken either
predose, 4 to 6 h postdose, or 8 to 10 h postdose.
Drug quantification. Each 4-ml blood sample, collected in a heparin-
ized vacuumplastic tube, was centrifuged at 750 g for 10min to separate
the plasma using a benchtop centrifuge. Samples were kept on crushed ice
during preparation, and the plasma aliquots were stored at 80°C until
drug quantification within 30 min of sampling. Concentrations of gati-
floxacin in plasma were quantified using high-performance liquid chro-
matography (HPLC) coupled to tandem mass spectrometry (MS). Inter-
and intraday coefficients of variation were below 10%. The lower limit of
quantification was set at 0.2 g/ml for pyrazinamide and 0.1 g/ml for
rifampin, gatifloxacin, and isoniazid (8).
Population pharmacokinetic analysis. Data analysis was performed
with a nonlinear mixed-effects approach, as implemented in NONMEM
software, version 7.1.2 (Icon Development Solutions) (17), using Advan
13 and the first-order conditional estimation method with interaction
(FOCE Inter). R (version 2.12.1) was used for graphical analysis and data
management (18). Xpose (version 4.0) was used for data exploration and
visualization as well as model diagnostics and model comparison (19).
PsN, version 3.3.2 (20, 21), was used for stepwise covariatemodel building
(SCM) (22), visual predictive checks (VPCs) (23, 24), and prediction-
corrected VPCs (pcVPCs) (25) of the models. Model selection was per-
formed using the objective function value (OFV) (which is minus twice
the log likelihood of the data), standard error of parameter estimates,
scientific plausibility, and goodness-of-fit plots together with VPC and,
when indicated, pcVPC.
A total of 954 gatifloxacin concentration observations from 169 pa-
tients were included in the analysis. Twelve observations, from 12 indi-
viduals, falling below the lower limit of quantification (LLOQ 0.1 g/
ml) were replaced with LLOQ/2. There was not more than one LOQ
observation in each individual absorption or elimination phase. One- and
two-compartment distribution models with first-order elimination were
fitted to the data. Potential differences in gatifloxacin pharmacokinetic
parameters were evaluated after initial and multiple doses. A transit ab-
sorption compartmentmodel described by Savic et al. (26) and applied by
Wilkins et al. (27) for multiple dosing was used to capture the delay in the
absorption characteristics. The absorption model used hypothetical tran-
sit compartments to mimic a delay in the onset of absorption, producing
a gradual increase in absorption rate in a physiologically plausible man-
ner. Drug transfer between transit compartments occurred via the rate
constant ktr (equation 1):
ktr
N 1
MTT
(1)
where MTT is the mean transit time and N is the number of transit com-
partments. Drug transfer from the final transit compartment to the cen-
tral compartment occurred via the first-order rate constant ka.
Creatinine clearance (CLCR) was estimated from serum creatinine us-
ing the Cockcroft-Gault formula (28) (equation 2):
CLCR
140 age · MASS · K
serum creatinine
(2)
where CLCR is in ml/min, serum creatinine is in nmol/ml, age is recorded
in years,K represents a constant of 1.23 for men and 1.04 for women, and
MASS is the total body weight recorded in kilograms.
As gatifloxacin is excreted primarily via the kidneys (1), typical oral
clearance, TV(CL/F), was parameterized as the sum of TV(CL/FGFR)
(where GFR stands for glomerular filtration rate), accounting for drug
passively filtered via the kidneys, and TV(CL/Fother), accounting for the
remaining drug clearance (equation 3):
TV
CL
F
 TV
CL
FGFR
 TV
CL
Fother
(3)
The relationship between TV(CL/FGFR) and CLCR was parameterized us-
ing equation 4.
TV
CL
FGFR
  CLFGFRSTD ·  CLCR,iCLCRmedian (4)
where (CL/FGFR)STD is the oral clearance in a typical patientwith amedian
CLCR of 94 ml/min and CLCR,i is the individual CLCR. TV(CL/Fother) was
scaled to a body size descriptor (MASS) and reported for a typical 70-kg
patient [(CL/Fother)STD] (equation 5):
TV
CL
Fother
  CLFotherSTD · MASS70 
3
4
(5)
Allometric scaling, using various size descriptors (MASS), namely, total
body weight (WT) (29, 30, 31, 32), fat-free mass (FFM) (32, 33), and
normal fatmass (NFM) (33), was evaluated for bothTV(CL/Fother) (equa-
tion 5) and the typical apparent volume of distribution, TV(V/F) (equa-
tion 6):
TV
V
F
 VF STD · MASS70  (6)
where (V/F)STD is the typical apparent volume of distribution.
NFM was expressed for TV(CL/Fother) (equation 7) and TV(V/F)
(equation 8) as described by Anderson and Holford (33).
NFMi FFMi Ffat CL
Fother
· WTi FFMi (7)
NFMi FFMi FfatV
F
· WTi FFMi (8)
where (Ffat)CL/F other and (Ffat)V/F denote the estimated unique contribu-
tion of fat mass (i.e., body weight minus FFM) to CL/Fother and V/F,
respectively.
Individual FFM values (FFMi) were calculated as
FFMi
WHSMAX · HT
2 · WT
WHS50 · HT
2WT
(9)
where WHSMAX is 42.92 kg/m
2 and WHS50 is 30.93 kg/m
2 in men,
WHSMAX is 37.99 kg/m
2 and WHS50 is 35.98 kg/m
2 in women, HT is
height in meters, and WT is total body weight in kg.
Interindividual variability (IIV) was modeled exponentially for all pa-
rameters. Furthermore, interoccasional variability (IOV) in the pharma-
cokinetic parameters was explored for all parameters (34). Covariance
between parameters was also tested. Different residual error models were
investigated, including proportional and slope-intercept models. Shrink-
age was calculated for fixed and random effects as 1 SD ()/, where 
is the between-individual and -occasion variation term and  is the pop-
ulation model estimate of the standard deviation in .
Once the basic model was developed, a covariate analysis was per-
formed using stepwise covariate model building (SCM) (22) as imple-
mented in PsN version 3.3.2 (20, 21). Sex, age, HIV status, and study site
(South Africa versusWest Africa) were investigated as covariate effects on
the following parameters: CL/FGFR, CL/Fother,V/F, ka,MTT, and bioavail-
ability (F). In the SCM, each parameter-covariate relationship was tested
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in a univariate fashion within NONMEM. The covariate model that re-
sulted in the best fit was carried forward to a multivariate search in which
the remaining parameter-covariate relations were included based on a 5%
significance level, and it was referred to as the “full forward model.” After
identification of the full forward model, a backward deletion was per-
formed to determine the final model. In the backward-deletion step, each
parameter covariate relationship was left out one at a time and tested
using a statistical significance criterion of 0.01%. This step was repeated
until no further covariate could be excluded, and the resulting model was
referred to as the “final model.” Continuous covariates were first intro-
duced in a linear fashion (fractional change) and centered on the median
covariate value. If a continuous covariate was included in a linear fashion,
inclusion according to a nonlinear fashion (i.e., piece-wise linear, expo-
nential, and power equation) was also tested. For categorical covariates,
models were expressed as fractional change from the typical value.
Based on the final model, the AUC from zero hour to infinity
(AUC0–) was derived to describe exposure after the first dose and at
steady state (day 28), respectively. Total oral clearance was simulated for
10,000 virtual patients and AUC0– derived through the following equa-
tion:
AUC0 
F · dose
CL
(10)
The individual percentage change in AUC0– between first dose and
steady state was calculated and reported as median (5th and 95th percen-
tiles). The 10,000 virtual patients were derived by resampling subjects
from the data used to develop the model.
As a pharmacokinetic/pharmacodynamic (PK/PD) index, we used the
ratio of the day 28 free gatifloxacin AUC for a 24-h dosing interval and the
MIC (fAUC/MIC), which has been shown to correlate to clinical outcome
(35). The target PK/PD index was defined as fAUC/MIC of125, which
corresponds to a surrogate for maximal bactericidal effect and reduced
probability of resistance (13, 14). The probability of target attainment
(PTA) (36) was investigated with Monte Carlo simulations. The final
model describing the pharmacokinetics in our study population was used
together with theMICdistribution from an in vitro study investigating the
activity of gatifloxacin against 234 clinical strains of M. tuberculosis iso-
lated in the southeast of Spain, published by Rodriguez et al. (3), with a
MIC range of 0.06 to 16 g/ml. The median MIC50 from the aforemen-
tioned study was 0.125 g/ml, while the median MIC90 was 0.25 g/ml
with only 6 strains (2.5%) having MICs of	0.25 g/ml.
The acceptable level for the PTA is still under debate, as is the most
appropriate value for the target ratio of fAUC/MIC for optimal activity of
gatifloxacin against M. tuberculosis. Therefore, the target ratio of fAUC/
MIC as a function of theMIC with the 80% and 90% confidence intervals
(CI) was derived. The lower boundary in an 80%CI of the total probabil-
ity function is equivalent to 90% PTA (36). The PK/PD breakpoint was
defined as the MIC at which the calculated PTA was 90%.
Ten thousand individual fAUCs were simulated based on the final
model by integrating predicted drug concentrations from 0 to 24 h at
steady state and thereafter correcting for serum protein binding, which
was assumed to be 20% (1, 37). The PTA, i.e., the probability of fAUC/
MIC being 125 across the range of MICs described by Rodriguez et al.
(3), was derived. The cumulative fraction of response (CFR) (36) was
calculated, representing the proportion of the population achieving
fAUC/MIC of 125, given Monte Carlo simulation and the MIC distri-
bution ofM. tuberculosis for 400, 600, and 800 mg once daily of gatifloxa-
cin at steady state in combination with rifampin, isoniazid, and pyrazin-
amide. The CFR was calculated using equation 11:

i1
n
PTAi  Fi (11)
where i indicates the MIC category ranked from lowest to highest MIC
value, PTAi is the PTAof eachMIC category, and F is the fraction of theM.
tuberculosis population at each MIC category. F was calculated at each
MIC as the number of isolates divided by the total number of isolates
(234) yielding the frequency for each MIC.
RESULTS
The characteristics of the 169 patients contributing to this analysis
are described in Table 1. More than one-half (59%) of the study
participants were recruited at the South African study site, which
had the highest frequency of HIV-infected patients (52% versus
12% in Benin and none in Guinea or Senegal).
The final gatifloxacin pharmacokinetic model described
one-compartment with first-order elimination. Including an
absorption transit model to account for the delay in absorption
resulted in a drop in OFV of 125 points. The relationship be-
tween CLCR and CL/F was described using equations 3 and 4
based on the prior knowledge that gatifloxacin is largely elim-
inated by the kidneys (1), and this resulted in OFV reductions
of 19 and 24 points, respectively, compared to models not ac-
counting for CLCR or a combination of GFR-mediated- and
non-GFR clearance. In a 70-kg patient, gatifloxacin total CL/F
was estimated to be 11.28 liters/h. Approximately 55% (6.17
liters/h) of CL/F was accounted for by renal filtration (a route
scaled with CLCR). Allometric scaling was applied to the re-
maining 45% (5.11 liters/h) of CL/F and to V/F (141 liters/h)
using FFM as the optimal size descriptor, and the estimates
were reported for a 70-kg patient (Table 2). F was 11.7% lower
at steady state (day 28) than at the first dose. Age, sex, and HIV
status had significant effects on the absorption rate constant,
reducing interindividual variability of the parameter by 6.5,
3.4, and 17.7%, respectively (Table 2). The final model ade-
quately described the concentration in plasma-time data at ini-
tial dose and at steady state as judged by the VPC (Fig. 1).
Shrinkage for random effects between individuals and occa-
sions ranged from 17 to 25% and from 38 to 99%, respectively.
Shrinkage rates in IIV and IOV for CL/F were 25% and 42%,
respectively. The epsilon (residual error) shrinkage was 39%.
Based on 10,000 Monte Carlo patient simulations, the median
AUC0– (41.2 g · h/ml after the first dose) decreased to 35.4 g ·
TABLE 1 Demographics and covariates of patients included in the gatifloxacin population pharmacokinetic modela
Characteristic (unit) All sites South Africa Senegal Benin Guinea
Total no. of patients 169 99 26 25 19
No. of males/no. of females 116/53 62/37 23/3 20/5 11/8
No. of HIV
 patients 54 51 0 3 0
FFM (kg) 45 (39–49) 45 (38–48) 49 (46–52) 46 (41–48) 45 (35–46)
Body wt (kg) 55 (51–60) 56 (51–61) 55 (52–59) 53 (46–57) 52 (50–55)
Age (yr) 29 (24–35) 30 (24–35) 28 (25–31) 30 (26–37) 25 (20–34)
CLCR (ml · min
1) 94 (81–110) 100 (85–111) 87 (82–102) 75 (63–87) 89 (78–99)
a Continuous variables are given as medians, with interquartile ranges in parentheses. FFM, fat-free mass; CLCR, creatinine clearance.
Smythe et al.
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h/ml at steady state, following daily 400-mg doses of gatifloxacin
in combination with rifampin, isoniazid, and pyrazinamide (Fig.
2). The median decrease in AUC0– was 14.3% (5th and 95th
percentiles,90.4%,
61.5%).
The PTA, i.e., the probability of patients achieving or exceed-
ing the fAUC/MIC ratio of 125 at steady state, given the frequency
distribution of MICs reported from 234 clinical isolates of M.
tuberculosis, is shown in Fig. 3. The CFR, i.e., the proportion of the
population achieving an fAUC/MIC of 125 for daily 400-mg
doses of gatifloxacin in combinationwith rifampin, isoniazid, and
pyrazinamide, was calculated to be 61.4%. The respective CFRs
for 600- and 800-mg doses of gatifloxacin were 79.3% and 88%.
The PK/PD breakpoint, defined as the MIC at which the calcu-
lated PTAwas90%, was 0.125g/ml for daily gatifloxacin doses
TABLE 2 Parameter estimates based on the final gatifloxacin
pharmacokinetic modela
Parameter (unit) Estimate % RSE
(CL/FGFR)STD (liters/h) 6.17 9.7
(CL/FOther)STD (liters/h) 5.11 15.4
(V/F)STD (liters) 141 2.7
Ffirst dose 1 FIX
Fsteady state (% change from Ffirst dose) 11.7 17.4
ka (h
1) 4.13 13.5
MTT (h) 0.65 8.1
N 12.6 19.7
Covariate relationships
AGE-ka (%) 3.2 15.2
SEX-ka (%) 54.8 10.7
HIV
-ka (%) 61.9 38.4
IIV
IIVCL/F (%) 33.0 7.7
IIVV/F (%) 22.1 10.9
IOV
IOVCL/F (%) 33.0 5.7
IOVV/F (%) 13.2 13.9
IOVMTT (%) 44.9 12.3
Residual variability
Additive error (g/ml) 0.341 5.1
Proportional error (%) 7.35 12.5
Predose additive error (g/ml) 0.0418 40.7
a IIV, interindividual variability expressed as coefficient of variation; IOV, interoccasion
variability expressed as coefficient of variation; RSE, relative standard error reported on
the approximate standard deviation scale; (CL/FGFR)STD, the oral clearance in a typical
patient with a median CLCR of 94 ml/min, representing drug cleared via glomerular
filtration (GFR); (CL/FOther)STD, the oral clearance not due to GFR in a typical 70-kg
male patient and with a fat-free mass (FFM) of 55 kg. (V/F)STD, typical apparent
volume of distribution scaled to FFM and reported for a 70-kg male patient; F,
bioavailability; MTT, mean transit time; N, number of transit compartments; AGE-ka,
% increase in ka for every year change from the median AGE of 29 years; SEX-ka, %
decrease in ka for female patients relative to male patients; HIV

-ka (%), % increase in
ka for patients with HIV relative to patients without HIV; predose additive error (g/
ml), additive error estimated uniquely for the predose concentrations following an
unobserved dose; 1 FIX, fixed to 1 (not estimated).
FIG 1 Visual predictive check (VPC) of the final gatifloxacin pharmacokinetic model stratified by occasion, i.e., first dose (a) and steady-state (day 28) (b). The
solid line and the two dashed lines are themedian and 5th and 95th percentiles, respectively, of the observed gatifloxacin concentrations in plasma. Shaded areas
are the 90% prediction intervals for the median and 5th and 95th percentiles of simulated data. The open circles are observed concentrations.
FIG 2 Box plot of gatifloxacin area under the concentration-time curve from
0 h to infinity (AUC0–) at first dose and at steady state (day 28) based on
10,000 virtual patients and Monte Carlo simulations of 400 mg gatifloxacin
daily together with rifampin, isoniazid, and pyrazinamide. In this population,
the median gatifloxacin AUC0– of 41.2 g · h/ml (5th and 95th percentiles,
17.9 and 93.8) after the first dose was reduced on an individual level by 14.3%
(5th and 95th percentiles, 90.4 and 61.5) to 35.4 g · h/ml (5th and 95th
percentiles, 15.2 and 80.4) at steady state (day 28).
Population Pharmacokinetics of Gatiﬂoxacin
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of 400 mg and 0.25 g/ml for 800-mg doses of gatifloxacin
(dashed line in Fig. 3). The fAUC/MIC as a function of theMIC is
shown for 400-, 600-, and 800-mg doses in Fig. 4.
DISCUSSION
In our study, gatifloxacin exposure (bioavailability) was reduced
following multiple doses when given together with rifampin, iso-
niazid, and pyrazinamide. This is in contrast to a single-dose study
in healthy volunteers in which increased gatifloxacin exposure
(AUC0–) was observed (8). Hence, any initial increase in gati-
floxacin concentrations attributable to concomitant use of rifam-
pin, isoniazid, and pyrazinamide was counteracted by a reduction
in gatifloxacin concentrations with repeated doses of the four
drugs in combination. Exposure-related toxicity is thus unlikely
to increasewith repeated doses of gatifloxacinwhen it is givenwith
rifampin, isoniazid, and pyrazinamide.
Two interesting observations emerge when comparing expo-
sure after single-agent and combination treatment. First, the
steady-state gatifloxacin AUC achieved in our study was slightly
lower than the steady-state AUC reported in studies where pa-
tients were given the drug alone (6, 38). Second, gatifloxacin phar-
macokinetic parameters (including bioavailability) were reported
not to change following multiple doses when the drug was given
on its own (1, 39). Gatifloxacin is a known substrate of the trans-
membrane efflux transporter protein P-glycoprotein (Pgp) (40),
and rifampin induces the expression of Pgp (41). Hence, repeated
doses of rifampinmay result in reduced gatifloxacin systemic bio-
availability due to increased efflux by Pgp expressed on entero-
cytes and hepatocytes. Gatifloxacin is principally (	80%) cleared
unchanged via the kidneys (1). The overall reduction in gatifloxa-
cin concentrations, following multiple doses in combination with
FIG 4 Median (solid thick line) total probability function, irrespective of the
target, as a function of the Mycobacterium tuberculosis (MTB) MIC, with the
80th (solid lines) and 90th (dashed lines) percentiles following daily adminis-
tration of 400 (a), 600 (b), and 800 (c) mg of gatifloxacin together with rifam-
pin, isoniazid, and pyrazinamide. The lower boundary in the 80th percentile of
the total probability function is equivalent to 90%PTA. The dashed horizontal
line indicates the reference line (fAUC/MIC 125).
FIG 3 The probability of target attainment (PTA) versus Mycobacterium tu-
berculosis (MTB)MIC following daily administration of 400mg (dashed line),
600 mg (solid line), and 800mg (long dash-dot-dot line) gatifloxacin together
with rifampin, isoniazid, and pyrazinamide based on 10,000 virtual patients
and Monte Carlo simulations. The PTA was defined as the probability of
achieving the target PK/PD index ratio of the area under the unbound concen-
tration versus time curve from 0 h to infinity at steady state (fAUC) divided by
MIC (fAUC/MIC) of 125 (a correlate of maximal bactericidal effect and
reduced probability of resistance (10, 40). The dashed horizontal line indicates
the reference line of 90% PTA. The solid drop lines with crosses () represent
the frequency distribution for MIC of gatifloxacin (y axis on the right) ob-
tained from 243 clinical isolates ofM. tuberculosis (37).
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rifampin, isoniazid, and pyrazinamide, is thus likely to be the net
result of drug-drug interactions observed both following single
doses and at steady state.
Reduced gatifloxacin clearance and recovery in urine were re-
ported following concomitant dosingwith probenecid, suggesting
that tubular secretionmay contribute to its elimination (1). In our
study, gatifloxacin clearance increased with creatinine clearance
(CLCR) and patient weight (FFM). Scaling drug clearance to both
FFM and CLCR allowed us to estimate that approximately 53% of
the dose was cleared via glomerular filtration. Using CLCR as our
proxy for renal filtrationmight, however, overestimate the contri-
bution of this pathway to drug clearance, since creatinine is ac-
tively secreted by the peritubular capillaries of the kidney (42).
The remaining 47% of gatifloxacin’s clearance was scaled to FFM
and accounted for drug cleared via all pathways other than glo-
merular filtration.
Gatifloxacin bioavailability was predicted to be approximately
12% lower at steady state than after an initial dose. This, combined
with increased patient weight (FFM) andCLCR (ml ·min
1) at the
second occasion, resulted in a 14.3% reduction of AUC0– at
steady state. The reduction in gatifloxacin exposure following
multiple doses is unlikely to be clinically significant, as on an in-
dividual level gatifloxacin AUC0– could increase by as much as
90% or decrease by as much as 62% between the two occasions
due to the high IOV in CL/F. Age, sex, and HIV infection status
were also identified as having significant covariate effects on the
absorption rate constant. However, these covariates are also un-
likely to be clinically relevant, as changes of the absorption rate do
not alter the average steady-state concentration.
Based on 10,000 Monte Carlo simulations using the final
model, 62, 79, and 88% of our study population were predicted
to achieve the target fAUC/MIC ratio of 125 following daily
400-, 600-, and 800-mg respective doses of gatifloxacin. Only
when theMIC of gatifloxacin fell below 0.125g/ml could 90%
of the study population, irrespective of dose, achieve the target
ratio. The simulations showed that at 800-mg daily doses of
gatifloxacin, approximately 90% of the population would
achieve the target ratio when the MIC was0.25 g/ml. These
results suggest that the current 400-mg daily dosing of gati-
floxacin does not achieve optimal drug exposure with respect
to theMIC distribution used. However, using the target plasma
fAUC/MIC ratio of 125 to predict the optimal dose of gati-
floxacin in this context is a simplification and has its limita-
tions. Forrest et al. (13) demonstrated that bacteriological and
clinical outcomes correlated best with the pharmacodynamic
index of an AUC/MIC of125 in 74 acutely ill patients treated
with ciprofloxacin for lower respiratory tract infections. In that
study, an AUC/MIC ratio of 125 was significantly correlated
with a faster bacterial eradication rate, which may decrease the
likelihood of antibacterial resistance. Setting the target to a
lower value (i.e., targets of AUC/MIC ratios of 125) could
potentially create needless selective pressure, increasing the
chance of resistance especially with a long duration of therapy
(e.g., 4 months). Notably, in a review by Schentag et al. (14),
the pharmacodynamic index target AUC/MIC ratio of125 is
recommended for both Gram-positive and Gram-negative or-
ganisms. Although fAUC/MIC is widely accepted as a correlate
of fluoroquinolone efficacy (43), more work is required to de-
termine whether an AUC/MIC of125 truly correlates with in
vivo efficacy against M. tuberculosis. In this work, we also pres-
ent the total probability function for different gatifloxacin
doses, which is not dependent on the target (Fig. 4). The lower
boundary in the 80th percentile of the total probability func-
tion is equivalent to 90% PTA. The 90% PTA for any new
future target can be visualized from this plot. Interestingly, a
plasma AUC/MIC ratio of 112 to 220 was associated with op-
timal survival among patients with tuberculosis meningitis
who were treated with a regimen containing gatifloxacin, levo-
floxacin, or ciprofloxacin in addition to standard antitubercu-
losis treatment (44). Although this ratio is in keeping with the
target AUC/MIC of 125, the optimal values for the plasma
AUC/MIC ratios for pulmonary tuberculosis and tuberculosis
meningitis are likely to differ due to differences in tissue pen-
etration and immunity at the site of action. Drug action occurs
within pulmonary compartments, including epithelial cells
and macrophages, where drug concentrations exceed those
found in plasma (45). Assuming higher fAUC in pulmonary
compartments, more patients could achieve the target fAUC/
MIC ratio of125. On the other hand, there are concerns that
administering higher doses of gatifloxacin would increase the
risk of toxicity such as dysglycemia. Lastly, the optimal dose of
gatifloxacin would need to take into account the efficacy and
safety profiles of the drug in the context of the contributions
from companion drugs in the multidrug regimen and patient
immunity.
Further limitations of our study include failure tomeasure free
gatifloxacin concentrations and lack of study-specific information
about the MICs. We assumed a 20% plasma protein binding for
gatifloxacin that is independent of concentration (1), and we used
the MIC distribution obtained from 234 clinical isolates of M.
tuberculosis from Spain (3). The M. tuberculosis population re-
ported in the Spanish study was slightly more sensitive to gati-
floxacin than to moxifloxacin and levofloxacin, with reported
MIC90s of 0.25 and 0.5g/ml, respectively. In agreement with the
Spanish study, a similar gatifloxacin MIC90 of 0.25 g/ml was
reported against clinical isolates ofM. tuberculosis obtained from
numerous sources with broad geographical distribution (46). Ad-
ditionally, the aforementioned study reported an MIC50 and dis-
tribution range ofMIC forM. tuberculosis similar to that reported
in the Spanish study. Thus, our assumption that the frequency
distribution of gatifloxacin MIC reported in the Spanish study
correlates to the MIC distribution found within our study popu-
lation appears to be valid. Nonetheless, as demonstrated by Pelo-
quin et al. (38), a change in the MIC distribution (i.e., published
versus actual MICs determined from clinical isolates obtained
from study patients) can radically change the fAUC/MIC ratio.
Since our study did notmeasure theMICs ofM. tuberculosis in the
study population, it is feasible that the true effectiveMIC could be
lower. Moreover, the MICs reflect the activity of gatifloxacin
alone; we did not account for synergism or antagonismwithin the
regimen. The relevance of these findings needs to be evaluated
alongside the eventual clinical outcomes of the study overall.
Conclusion.Although increased gatifloxacin exposurewas ob-
served in a previous single-dose study, gatifloxacin exposure, ex-
pressed as AUC0–, declined following multiple doses of the 4
drugs in the multidrug regimen. Hence, exposure-related toxicity
is unlikely to increase with repeated doses of gatifloxacin when
given concomitantly with rifampin, isoniazid, and pyrazinamide.
Based on predictions of fAUC/MIC and the derived proportion of
the population achieving optimal bactericidal effect and reduced
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probability of resistance (CFR), the CFR of the clinically used dose
of 400 mg daily was 61%; simulations showed that doubling the
dose would result in increasing the CFR to 88%. However, the
pharmacokinetics of gatifloxacin needs to be studied in relation to
efficacy and safety in pulmonary tuberculosis patients on themul-
tidrug regimen in order to evaluate the optimal gatifloxacin expo-
sures in this context.
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